Int. J. Mol. Sci. 2013, 14(1), 2085-2103; https://doi.org/10.3390/ijms14012085
Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening
Alexandros Laios 1,2,†, Bashir M. Mohamed 3,†, Lynne Kelly 1, Richard Flavin 2, Stephen Finn 2
, Lynda McEvoy 1,2, Michael Gallagher 2, Cara Martin 2, Orla Sheils 2, Martina Ring 2, Anthony Davies 3, Margaret Lawson 4, Noreen Gleeson 1, Tom D'Arcy 1, Charles D'Adhemar 2, Lucy Norris 1, Ream Langhe 1,2, Feras Abu Saadeh 1, John J. O'Leary 2,*
and Sharon A. O'Toole 1,2,*
, Lynda McEvoy 1,2, Michael Gallagher 2, Cara Martin 2, Orla Sheils 2, Martina Ring 2, Anthony Davies 3, Margaret Lawson 4, Noreen Gleeson 1, Tom D'Arcy 1, Charles D'Adhemar 2, Lucy Norris 1, Ream Langhe 1,2, Feras Abu Saadeh 1, John J. O'Leary 2,*
and Sharon A. O'Toole 1,2,*
1
Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland
2
Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James's Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland
3
Department of Clinical Medicine, Trinity College Dublin, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland
4
Department of Histopathology, St. James's Hospital, Dublin 8, Ireland
â€
These authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Received: 7 November 2012 / Revised: 5 January 2013 / Accepted: 6 January 2013 / Published: 22 January 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
Abstract
Platinum resistance is a major cause of treatment failure in ovarian cancer. We previously identified matrix metalloproteinase 9 (MMP-9) as a potential therapeutic target of chemoresistant disease. A2780cis (cisplatin-resistant) and A2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used. The cytotoxic effect of MMP-9/MMP-2 inhibitor, (2R)-2-[(4-Biphenylsulfonyl) amino]-3 phenylpropionic acid (C21H19NO4S) alone or in combination with cisplatin was determined using high content screening. Protein expression was examined using immunohistochemistry and ELISA. Co-incubation of cisplatin and an MMP-9/MMP-2 inhibitor, (2R)-2-[(4-Biphenylsulfonyl) amino]-3 phenylpropionic acid (C21H19NO4S) resulted in significantly greater cytotoxicity as compared to either treatment alone in a cisplatin resistant MMP-9 overexpressing cell line; A2780cis. In addition, pre-incubating with MMP-9i prior to cisplatin further enhances the cytotoxic effect. No significant difference was observed in MMP-9 protein in tissue but a trend towards increased MMP-9 was observed in recurrent serum. We propose that MMP-9/MMP-2i may be utilized in the treatment of recurrent/chemoresistant ovarian cancers that overexpress MMP-9 mRNA but its role in vivo remains to be evaluated. View Full-Text
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Laios, A.; Mohamed, B.M.; Kelly, L.; Flavin, R.; Finn, S.; McEvoy, L.; Gallagher, M.; Martin, C.; Sheils, O.; Ring, M.; Davies, A.; Lawson, M.; Gleeson, N.; D'Arcy, T.; D'Adhemar, C.; Norris, L.; Langhe, R.; Saadeh, F.A.; O'Leary, J.J.; O'Toole, S.A. Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening. Int. J. Mol. Sci. 2013, 14, 2085-2103.
Related Articles
Article Metrics
Comments
[Return to top]
Int. J. Mol. Sci.
EISSN 1422-0067
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert